Mastodawn

Cellular senescence is a biological stress response where cells cease dividing but do not die, instead lingering in tissue and emitting a toxic cocktail of inflammatory signals. In the liver, immune cells known as macrophages can enter this "zombie" state, continuously accumulating and driving the chronic inflammation associated with both aging and fatty liver disease.
#CellBiology #Immunology #Hepatology #Gerontology #MolecularBiology #sflorg
https://www.sflorg.com/2026/04/cbio04162602.html

UCLA scientists identify zombie immune cells as a driver of fatty liver disease, inflammation and aging

The study found that excess dietary cholesterol, not just aging alone, can push these immune cells into a permanently inflamed state, suggesting that

GastroAGI Mar 19

🎯 HCC treatment is evolving…
TACE + immunotherapy + targeted therapy shows stronger outcomes—but are we ready to change practice?

⚠️ Promising data, but guidelines still need phase III confirmation

#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd

All Scientifical Feb 18

A common symptom of advanced cirrhosis is:
A. Joint pain
B. Yellowing of the skin (jaundice)
C. Vision loss
D. Hearing loss
#cirrhosis #liverhealth #hepatology #livercirrhosis ... Continue to: https://www.facebook.com/1130092409221646/posts/1257987026432183

unitedvrg.com Feb 16

Clinical dilemmas in non-alcoholic fatty liver disease 1st Edition (2016) by Professor Roger Williams CBE
Author: Professor Roger Williams CBE
File Type: PDF
Download at https://unitedvrg.com/2023/01/04/pdf-clinical-dilemmas-in-non-alcoholic-fatty-liver-disease-1st-edition-2016-by-professor-roger-williams-cbe/
#Hepatology, #ProfessorRogerWilliamsCBE

GastroAGI Feb 10

Nutrition is central in cirrhosis care. Malnutrition, sarcopenia, and frailty worsen transplant outcomes.

Early assessment, adequate calories, and high-quality protein prehabilitation preserve muscle and resilience. The waitlist is a window to intervene.

#Cirrhosis #Hepatology #TransplantMedicine #NutritionInCirrhosis #Sarcopenia #MedicalEducation #EvidenceBasedMedicine #GastroAGI

GastroAGI Feb 10

GastroAGI is an AI-powered knowledge platform for gastroenterology & hepatology—built for clinicians, trainees, and researchers.

Evidence-first answers from journals, guidelines, and conferences. No noise. No hallucinations. Just clarity.

#GastroAGI #Gastroenterology #Hepatology #MedicalAI #EvidenceBasedMedicine #MedEd #ClinicalPractice #GIResearch

GastroAGI Feb 10

COBALT Trial (PBC): Despite early termination, adjusted analyses + real-world external controls showed obeticholic acid (OCA) reduces major liver events.

EC (External Control) analysis: 60% risk reduction in the risk of adverse clinical outcomes like death, liver transplantation, or hepatic decompensation.(HR 0.39).

Well-tolerated; pruritus most common.

Highlights power of hybrid RCT + real-world evidence.

#PBC #Hepatology #GastroAGI

All Scientifical Feb 5

Fatty degeneration of hepatocytes (fatty hepatosis) #hepatology #hepatocytes #liver #liverhealth ... Continue to: https://www.facebook.com/reel/25669765376050249/

GastroAGI Feb 2

🔬 GastroAGI — February 2026 Updates

February updates are live on GastroAGI, covering key areas in gastroenterology and hepatology, including Liver Transplantation, Endoscopy, IBD, GI Oncology, Upper GI disorders, Cirrhosis, and Fatty Liver Disease (MASLD).

Explore more: https://gastroagi.com

#Gastroenterology #Hepatology #MedEd #Endoscopy #IBD #MASLD